Skip Navigation


JAC Advance Access originally published online on February 4, 2005
Journal of Antimicrobial Chemotherapy 2005 55(3):312-316; doi:10.1093/jac/dki020
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/3/312    most recent
dki020v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gomez-Lopez, A.
Right arrow Articles by Cuenca-Estrella, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomez-Lopez, A.
Right arrow Articles by Cuenca-Estrella, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.55 no.3 © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review

Alicia Gomez-Lopez, Emilia Mellado, Juan L. Rodriguez-Tudela and Manuel Cuenca-Estrella*

Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra Majadahonda-Pozuelo Km 2, 28220 Majadahonda (Madrid), Spain

* Corresponding author. Tel: +34-91-5097961; Fax: +34-91-5097966; Email: mcuenca-estrella{at}isciii.es

Objective: In vitro susceptibility results of 29 clinical isolates of Rhodotorula spp. were analysed. In addition, the susceptibility profile of another 102 Rhodotorula isolates was reviewed.

Methods: The review included studies using antifungal susceptibility testing reference procedures or commercial methods exhibiting high correlation rates with reference procedures (Etest and Sensititre YeastOne). The 131 organisms analysed were 77 Rhodotorula mucilaginosa, 45 Rhodotorula glutinis and nine Rhodotorula spp.

Results and conclusions: Fluconazole, itraconazole and voriconazole were inactive in vitro against the majority of isolates. Amphotericin B and flucytosine exhibited good activity, being reasonable alternatives for empirical treatment. Ravuconazole was more active in vitro than other azole agents and it could be considered as an extended-spectrum triazole and maybe as a therapeutic alternative in treating infections caused by Rhodotorula species.

Keywords: Rhodotorula , susceptibility of emerging yeasts , fluconazole resistance , ravuconazole


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
S. N. Leaw, H. C. Chang, R. Barton, J.-P. Bouchara, and T. C. Chang
Identification of Medically Important Candida and Non-Candida Yeast Species by an Oligonucleotide Array
J. Clin. Microbiol., July 1, 2007; 45(7): 2220 - 2229.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, G. Garcia-Effron, A. Monzon, and J. L. Rodriguez-Tudela
In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi
Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5136 - 5138.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.